Nonetheless, our data show that inhibition of IGF-IR remained to be substantially effective in decreasing the viability of NPM-ALK+ T cell lymphoma cells resistant to ALK inhibition. The gene discussed is ALK; the disease is T-cell non-Hodgkin lymphoma.